All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Pirtobrutinib Yields Improved Efficacy Over BR in First-Line CLL/SLL

December 9th 2025

Pitrobrutinib monotherapy showed significant efficacy improvements in first-line CLL/SLL compared with BR treatments.

Zanubrutinib Plus Venetoclax Displays Long-Term PFS Benefit in Untreated CLL/SLL

December 9th 2025

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

FDA Approves Omidubicel for Adult and Pediatric Patients With Severe Aplastic Anemia

December 9th 2025

The FDA has approved the HSCT therapy for patients 6 years or older with SAA following reduced-intensity conditioning who do not have a compatible donor.

GLPG5101 Produces Responses With Manageable Safety in R/R NHL, MCL

December 9th 2025

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

MK-1045 Therapy Proves Active, Safe With Dose Modification in Relapsed/Refractory ALL

December 9th 2025

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL

December 9th 2025

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

Researchers Identify Strategy for Reducing Risk of Acute Graft-Versus-Host Disease for Many With Blood Cancers

December 9th 2025

Researchers at Roswell Park Comprehensive Care Center discover method of reducing acute graft-versus-host disease risk in blood cancers.

Tagraxofusp/Azacitidine/Venetoclax Triplet Is Safe, Feasible in First-Line and R/R BPDCN

December 8th 2025

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

Sonrotoclax Displays Activity in BTK Inhibitor–Pretreated R/R MCL

December 8th 2025

Sonrotoclax monotherapy led to an ORR of 52.4% and a CR rate of 15.5% in relapsed/refractory MCL.

MaaT013 Shows Tolerability, Early Efficacy in Refractory Acute GVHD With GI Involvement

December 8th 2025

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

Ziftomenib Plus Venetoclax and Azacitidine Is Tolerable and Active in NPM1/KMT2A+ AML

December 8th 2025

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

Ziftomenib at RP2D Demonstrates High Response Rates for NPM1-Mutated AML

December 8th 2025

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

Acalabrutinib/Rituximab Followed by Brexu-Cel Drives Responses in Untreated High-Risk Mantle Cell Lymphoma

December 8th 2025

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

Talquetamab Plus Teclistamab Displays Activity in R/R Multiple Myeloma With True EMD

December 8th 2025

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

Toripalimab Plus Chemo Maintains Survival Benefit After 6 Years in Recurrent/Metastatic NPC

December 8th 2025

The durable survival advantage seen with the regimen after 6 years of follow-up supports its use as a first-line treatment in nasopharyngeal carcinoma.

INCA033989 Nets FDA Breakthrough Therapy Designation in CALR-Mutated R/R Essential Thrombocythemia

December 8th 2025

The FDA has granted breakthrough therapy designation to INCA033989 in CALR-mutated essential thrombocythemia.

Linvoseltamab Generates Responses in Newly Diagnosed Myeloma

December 8th 2025

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma

December 8th 2025

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

CAMMA 3 Data Support Ongoing Investigation of Cevostamab in Heavily Pretreated Myeloma

December 8th 2025

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

Experts Highlight HR+ and TNBC Trials to Watch Ahead of SABCS 2025

December 8th 2025

Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.